Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Direct Oral Anticoagulant / AF

Edoxaban (AF / VTE)

Brand names: Lixiana

Used in: Venous Thromboembolism (DVT & PE)

Edoxaban is a direct oral anticoagulant (a factor Xa inhibitor) used for stroke prevention in non-valvular atrial fibrillation and for treatment and prevention of venous thromboembolism.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

US labelling (FDA)

Reference — US labelling, may differ from UK

Treatment of NVAF: Assess CrCL before initiating therapy ( 2.1 ) The recommended dose is 60 mg once daily in patients with CrCL >50 to ≤ 95 mL/min. Do not use SAVAYSA in patients with CrCL > 95 mL/min ( 2.1 ) Reduce dose to 30 mg once daily in patients with creatinine clearance 15 to 50 mL/min ( 2.1 ) Treatment of DVT and PE: The recommended dose is 60 mg once daily ( 2.2 ) Reduce dose to 30 mg once daily for patients with CrCL 15 to 50 mL/min or body weight less than or equal to 60 kg or who use certain P-gp inhibitors ( 2.2 ) 2.1 Nonvalvular Atrial Fibrillation The recommended dose of SAVAYSA is 60 mg taken orally once daily [see Warnings and Precautions (5.1) and Clinical Studies (14.1) …

Source: US FDA prescribing information (openFDA / DailyMed), label dated 2025-07-10. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.

Clinical monograph

How it works

It directly and reversibly inhibits activated factor X (factor Xa), reducing thrombin generation.

Prescribing in practice

  • Dose-reduction criteria apply (low body weight, renal impairment, certain P-glycoprotein inhibitors).
  • Unusually, in AF its efficacy is reduced at very high creatinine clearance — note the upper renal threshold as well as avoiding it in severe renal impairment.
  • For VTE it is started after an initial period of parenteral anticoagulation.

Monitoring

No routine coagulation monitoring; check renal and hepatic function and full blood count at baseline and periodically.

Counselling the patient

  • Take it regularly — protection wears off if doses are missed.
  • Report unusual bleeding.
  • Tell clinicians or dentists you take an anticoagulant.

Evidence & guidelines

DOACs are first-line for non-valvular AF (NICE NG196); edoxaban's AF evidence comes from ENGAGE AF-TIMI 48.

Reference: ENGAGE AF-TIMI 48 Trial (Giugliano et al. NEJM 2013); NICE TA355; SPC Lixiana; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways